Weichler U, Herres-Mayer B, Mayer J, Weber K, Hoffmann R, Peter J H
Medical Outpatient Department, Philipps-Universität Marburg, FRG.
Cardiology. 1991;78(2):124-30. doi: 10.1159/000174776.
Sleep apnea, which affects 10% of men in the mean age group, is a common illness, and arterial hypertension one of its early symptoms. For the large group of, mainly young, patients with mild to moderate sleep apnea and arterial hypertension it is important to have a drug treatment available which will effectively control blood pressure without exacerbating symptoms of sleep apnea. We studied the effects of antihypertensive agents on blood pressure, sleep and sleep apnea in a randomized double-blind study of 24 patients with a sleep apnea activity of more than 10 apnea phases per hour of sleep and arterial hypertension with diastolic blood pressure values in the sitting position greater than or equal to 95 mm Hg. Mean age was 51 (range: 33-69) years, mean body mass index 31.4 (24.9-40.6) kg/m2. The study protocol envisaged two baseline measurements in the sleep laboratory, after which the medication was administered for 8 days. On the last 2 days of the treatment, polysomnographic leads were once again recorded in the sleep laboratory. The patients received either the beta-blocker metoprolol (1 x 100 mg/day) or the angiotensin-converting enzyme inhibitor cilazapril (1 x 2.5 mg/day). Systolic and diastolic blood pressure were decreased by both substances as expected. Total sleep time was 358 (233-425) min vs. 332 (255-383) min in the metoprolol group and 368 (295-424) min vs. 341 (265-434) min in the cilazapril group which is statistically not different between the two groups nor between the proportions of non-REM and REM sleep.(ABSTRACT TRUNCATED AT 250 WORDS)
睡眠呼吸暂停是一种常见疾病,在中年男性群体中发病率为10%,动脉高血压是其早期症状之一。对于大量主要为年轻的轻度至中度睡眠呼吸暂停和动脉高血压患者而言,拥有一种能有效控制血压而不加重睡眠呼吸暂停症状的药物治疗方法非常重要。我们在一项随机双盲研究中,对24名睡眠呼吸暂停活动每小时超过10个呼吸暂停阶段且坐位舒张压值大于或等于95毫米汞柱的动脉高血压患者,研究了抗高血压药物对血压、睡眠和睡眠呼吸暂停的影响。平均年龄为51岁(范围:33 - 69岁),平均体重指数为31.4(24.9 - 40.6)千克/平方米。研究方案规定在睡眠实验室进行两次基线测量,之后给药8天。在治疗的最后2天,再次在睡眠实验室记录多导睡眠图导联。患者分别接受β受体阻滞剂美托洛尔(1×100毫克/天)或血管紧张素转换酶抑制剂西拉普利(1×2.5毫克/天)。两种药物均如预期降低了收缩压和舒张压。美托洛尔组的总睡眠时间为358(233 - 425)分钟,之前为332(255 - 383)分钟;西拉普利组为368(295 - 424)分钟,之前为341(265 - 434)分钟,两组之间以及非快速眼动睡眠和快速眼动睡眠比例之间在统计学上无差异。(摘要截断于250字)